Page last updated: 2024-11-05
3-bromopyridine
3-bromopyridine is a heterocyclic aromatic compound that serves as a versatile building block in organic synthesis. It is a key intermediate in the preparation of various pharmaceuticals, agrochemicals, and other fine chemicals. The compound can be synthesized through various methods, including bromination of pyridine using bromine in the presence of a catalyst, or by reaction of pyridine with N-bromosuccinimide. 3-bromopyridine has been shown to exhibit diverse biological activities, including antimicrobial, anti-inflammatory, and anticancer properties. Its importance in research stems from its potential applications in drug discovery and development. For example, it has been used as a starting material for the synthesis of several promising drug candidates, including inhibitors of enzymes involved in various disease processes. Additionally, 3-bromopyridine serves as a valuable reagent in the preparation of various functionalized heterocyclic compounds, expanding its utility in chemical synthesis and discovery.'
Cross-References
ID Source | ID |
PubMed CID | 12286 |
CHEBI ID | 51575 |
SCHEMBL ID | 6350 |
MeSH ID | M0507399 |
Synonyms (45)
Synonym |
einecs 210-952-0 |
unii-xmn8h2xe9h |
ai3-17853 |
xmn8h2xe9h , |
nsc 3974 |
3-bromopyridine , |
626-55-1 |
nsc-3974 |
nsc3974 |
pyridine, 3-bromo- |
inchi=1/c5h4brn/c6-5-2-1-3-7-4-5/h1-4 |
3-bromopyridine, 99% |
B0651 |
STK802249 |
AKOS000119193 |
A833908 |
3-bromopyridine;3-bromopyridine, stabilized with copper chip |
3-bromo-pyridine |
5-bromopyridine |
c5h4brn |
CHEBI:51575 |
3-pyridyl bromide |
BP-13125 |
FT-0615250 |
PS-4257 |
AM20061386 |
AB00739 |
CX1091 |
BBL027581 |
SCHEMBL6350 |
pyridin-3-yl bromide |
m-bromopyridine |
DTXSID9060819 |
3-bromo pyridine |
5-bromo-pyridine |
3-bromopryidine |
3-bromopyridin |
W-104971 |
STR04425 |
mfcd00006373 |
F0001-1682 |
BCP22223 |
CS-0008362 |
Q223057 |
EN300-19110 |
Drug Classes (1)
Class | Description |
monobromopyridine | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 36.93
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 36.93 (24.57) | Research Supply Index | 1.79 (2.92) | Research Growth Index | 4.63 (4.65) | Search Engine Demand Index | 45.80 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |